{
    "clinical_study": {
        "@rank": "121074", 
        "arm_group": {
            "arm_group_label": "Treatment group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients\n      with proven or probable fungal infections caused by Candida sp. (Fungemia, respiratory\n      mycosis, gastrointestinal mycosis) in adult patients in China."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Candidiasis", 
            "Candidemia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidemia", 
                "Candidiasis, Invasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  The diagnosis criteria of probable candida infection: Risk factors + Clinical\n             Manifestations + positive findings including microbiologic test\n\n          -  The diagnosis criteria of proven candida infection: Risk factors + Clinical\n             Manifestation + positive findings including microbiologic test + tissue culture or\n             pathological examination results\n\n          -  The following 3 criteria must be met is a patient is diagnosed as probable candida\n             pneumonia:\n\n               1. Risk factor (s) of infection\n\n               2. Clinical manifestations of infection and the pulmonary infection cannot be\n                  explained by other pathogenic infections\n\n               3. Two or more positive sputum culture for Candida\n\n        Exclusion Criteria:\n\n          -  Patient received any other antifungal drug within 1 month prior to enrollment.\n\n          -  HIV positive patient\n\n          -  Patients with organ transplant\n\n          -  Patients with agranulocytosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "109", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982071", 
            "org_study_id": "ACN-MA-MYC-IC-2012"
        }, 
        "intervention": {
            "arm_group_label": "Treatment group", 
            "description": "IV", 
            "intervention_name": "Micafungin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Micafungin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Open-label design", 
            "candidiasis", 
            "candidemia", 
            "Micafungin"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hengyang", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jinan", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nanjing", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shaoyang", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xi'an", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Xiamen", 
                        "country": "China"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "success rate is calculated as (number of success patients/number of patients for efficacy evaluation \u00d7 100% at end of treatment)", 
            "measure": "Overall success rate", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982071"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "up to 10 weeks"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma China, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}